Lexaria Bioscience receives patent in Canada

Lexaria Bioscience announced its continued accumulation of international patent recognition with the receipt of its first granted patent in Canada, which is its 28th granted patent worldwide. Canadian Patent #3,093,414 is the first granted patent from Lexaria’s sixth patent family and is entitled "Transdermal And/Or Dermal Delivery Of Lipophilic Active Agents". The patent is for improved compositions and methods for transdermal and dermal delivery of cannabinoids, including cannabidiol and tetrahydrocannabinol. Similar patent applications for skin-based delivery of DehydraTECH formulations remain pending in many other countries.